Virtual Library
Start Your Search
H. Koyi
Author of
-
+
ORAL 41 - Immune Biology, Microenvironment and Novel Targets (ID 159)
- Event: WCLC 2015
- Type: Oral Session
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:S.K. Padda, R. Nemenoff
- Coordinates: 9/09/2015, 18:30 - 20:00, Four Seasons Ballroom F1+F2
-
+
ORAL41.07 - The Identification of Therapeutic Targets in Lung Cancer Based on Transcriptomic and Proteomic Characterization of Cancer-Testis Antigens (ID 1555)
18:30 - 20:00 | Author(s): H. Koyi
- Abstract
- Presentation
Background:
Most immunotherapeutic modalities are based on the concept that the immune system can attack targets that are specifically expressed in cancer cells. Cancer testis antigens (CTAs) are a group of genes with a broad expression in cancers including non-small cell lung cancer (NSCLC). In normal tissues the expression of CTAs is restricted to immune privileged organs such as testis and placenta. This limited expression in somatic tissues renders CTAs as a valuable group of genes for the exploration of potential immunotherapeutic targets. The aim of this study was to comprehensively explore the CTA repertoire in NSCLC and to try identifying new CTAs.
Methods:
RNA sequencing (RNAseq) was performed on 202 NSCLC samples from a consecutive clinical cohort of surgically resected patients. For the analysis of the comprehensive CTA expression profile in NSCLC we used Cancer Testis (CT) Database containing all genes reported as CTAs in the literature. The NSCLC transcriptome was compared to the normal transcriptome comprising of 22 paired normal lung tissues as well as to 122 samples from 32 different normal human tissues. Corresponding protein expression was evaluated by using immunohistochemistry (IHC) on tissue microarrays (TMAs) containing tumor tissue from the same patients as used in the RNA sequencing.
Results:
Of the 276 established CTAs, 155 genes (56%) were restricted to testis and placenta among normal tissues and were identified as CTAs. One third (35%) was expressed in at least one of the 202 individual NSCLC cases and 28 of these genes were previously not reported to be expressed as CTAs in NSCLC. Applying stringent analysis criteria on our RNA sequencing data set we identified 61 genes that were expressed in NSCLC and testis or placenta, but not in other normal tissues. Thus, these genes present potential new CTAs. The specific cancer/testis expression of selected genes (ZNF560, TGIF2LX, TFPI2, HMGB3, TKTL1 and STK31) from this group was confirmed on protein level using IHC. Additional analysis revealed that most CTAs were concurrently expressed in adenocarcinoma and squamous cell carcinoma. The expression of a subset of genes was histology dependent, with predominant expression in adenocarcinoma (e.g. XAGE family members) and in squamous cell carcinoma (e.g. MAGE family members).
Conclusion:
Our study provides deep sequencing mRNA expression profiles of the whole CTA repertoire in NSCLC. Several CTAs previously identified in other cancers but not analyzed in NSCLC have been identified on both mRNA and protein level. Additionally, we have identified 61 novel genes as CTAs in NSCLC that previously have not been reported as CTAs and several of these were also confirmed on protein level. This data offers the opportunity to design individual therapy options to target single CTAs or CTA clusters.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.02-041 - Stereotactic Body Radiotherapy (SBRT) or Surgery in Early Stage (I & II) Non Small Cell Lung Cancer (NSCLC) (ID 1621)
09:30 - 17:00 | Author(s): H. Koyi
- Abstract
Background:
For patients with NSCLC clinical stages I and II disease with no medical contraindications, surgery is treatment of choice showing 5-year survival rates of about 60–80% for stage I and 40–50% for stage II, respectively. However, for patients who are medically or technically unfit for surgery and for patients refusing surgery, SBRT) is an alternative with local control rates >90% at 3 years.
Methods:
Medical journals in all patients with stage I or II NSCLC who were underwent surgery and treated with SBRT at the Department of oncology or thoracic surgery, Karolinska University Hospital, Sweden from 2003 to 2009 were retrospectively reviewed.
Results:
In all, 186 (78.2%) underwent surgery and 52 (21.8%) were treated with SBRT. Mean, median and range of age among the surgery group was 69.29, 70.52 and 45-85 years, while in the SBRT group, these figures were 78.04, 80.03 and 61-89 years. The difference in age between the groups was significant (p=0.03).There were significantly more comorbidites in the SBRT group. Among the surgery group, 91.3% were smokers or former smokers. The figures for SBRT group was 94.1%. There was a significant difference in performance status (PS) between the groups (p<0.001) with with PS 0-1 in 98.9% in the surgery group compared with 69.2% in the SBRT group. There was a significant difference in lung function with mean FEV1 2.15 liter in surgery group compared to 1.45 in the SBRT group. The figures for mean FEV1% was 83% respectively 57.5%. The median overall survival was 97 months for the surgery group and 61.8 months for the SBRT group (p<0.001).
Conclusion:
The much worse median overall survival in the SBRT group can be explained by the selection of patients, but still, a survival of more than 5 years in an elderly group with so many comorbidities and a bad PS indicates that SBRT has been of value.
-
+
P3.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 211)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.02-019 - Surgery in Elderly Patients ( > 70 Years or Older) with Non-Small Lung Cancer (NSCLC). Impact of Adjuvant Chemotherapy (ID 2243)
09:30 - 17:00 | Author(s): H. Koyi
- Abstract
Background:
Surgery remains the cornerstone of therapy for medically operable patients with early stage NSCLC. Differences in the frequency of surgery for patients with respect to their age, sex and socioeconomic deprivation have been described. Older patients have been found to be less likely to undergo surgery compared with younger patients even when they have similar performance status. Several randomized trials and meta-analyses have shown that adjuvant chemotherapy after resection of stages II–IIIA NSCLC improves survival.
Methods:
The medical records of all 164 patients ≥70 years, who underwent surgery for NSCLC from 2003 to 2009 at our department, were reviewed retrospectively.
Results:
One-hundred twenty-six given no adjuvant therapy. Eigthy-seven (52.4%) were male. Median mean and range of age male patients was 75.0, 74.8 and 70-85 years, while in females, these figures were 74.0, 75.5 and 70-84 years. Eighty-one (94.2%) of the males and 65 (82.3%) of the females were smoker/former-smoker. In both sexes 99% had performance status 0-1. Eighty-one (93.1%) of male patients and 71 (89.9%) of the females were stage I-II. Adenocarcinoma was the common histology in both sexes (55% of the males and 67.1% of the females). Squamous cell carcinoma came in second place, 31% respectively 20%. Lobectomi performed in 61 (84.1%) of the male patients and 62 (86.2%) female patients, left pneumonectomy in 6 (7.3%) male patients and 5 (6.9%) in female patients, right pneumonectomy in 1(1.4%) female patient. One-hundred twenty-six (77%) did not receive adjuvant therapy, mainly because of age. Median overall survival among all was 7.2 years, in the non-adjuvant group was 6.7 years and 7.6 years in the adjuvant group (p=0.5712).
Conclusion:
This single-institution series demonstrates that surgical intervention for appropriately selected elderly patients with NSCLC results in improved overall survival. Surgery should, therefore, be strongly considered for select patients ≥ 70 years of age with stage I/II and select stage IIIA NSCLC who have adequate pulmonary reserve.
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-021 - Mutation Profiling by Targeted Next-Generation Sequencing for Diagnostics and Patient Cohort Screening in FFPE NSCLC Samples (ID 920)
09:30 - 17:00 | Author(s): H. Koyi
- Abstract
Background:
Recent discovery of the landscape of somatic mutations in non-small cell lung cancer (NSCLC), and introduction of new therapeutics have raised the demands for multiplex mutation assays. In exploratory research, mutation profiling has largely been performed on fresh-frozen tissue from surgical specimens. However, for patients with advanced disease the assays need to be adapted to small formalin-fixed paraffin embedded (FFPE) biopsies and cytology preparations. Targeted next-generation sequencing (NGS) techniques are now being developed to address these challenges and have now reached the point where they are more cost efficient than previously used methods, hence there is a need to optimize and validate these techniques to determine if they are robust enough to work in clinical diagnostics.
Methods:
Here we have developed and evaluated Haloplex gene panels in comparison to pyrosequencing and quantitative PCR(qPCR), i.e. the current standard methods for molecular diagnostics of solid tumours in Sweden. The target enrichment was focused on short DNA fragments and included independent capture of complementary strands, “two strand capture”, to address fragmentation and base damage induced by formalin fixation. The panels include all exons of 18-32 genes (for lung cancer and other solid tumors respectively) with known clinical relevance. Seventy-one clinical samples (NSCLC, colorectal carcinoma and melanoma), with known mutational status of hotspots in KRAS, BRAF, NRAS, PIK3CA and EGFR, were selected for analysis. DNA was prepared from FFPE tissues and used for library preparation using the panels and subsequently sequenced on an Illumina MiSeq instrument.
Results:
A complete concordance was seen between the previously defined pyrosequencing and qPCR genotypes and the corresponding variants detected using the gene panels. Both point mutations and smaller indels (<25bp) could be detected by this technique using an in-house bioinformatic pipeline. False positive FFPE-induced mutation artefacts could reliably be identified by the two-strand filter. The technical sensitivity of mutation detection was determined to 2%, and we have decided to use a 5% variant allele frequency threshold for clinical reporting. In addition, clonality and subclonality could be discovered in patients with complex tumour disease (mixed or multiple tumour lesions) by analysis of the mutation patterns. An extended 85 gene panel has also been designed to screen for mutations in NSCLC patient cohorts for clinical molecular research.
Conclusion:
We believe that the established lung cancer gene panels for targeted enrichment and NGS can replace pyrosequencing and qPCR for molecular diagnostics in NSCLC, and will be useful for screening of unselected population-based prospective and retrospective lung cancer patient cohorts in clinical research.
